The future of drug discovery and development: Shifting emphasis towards personalized medicine

Technological Forecasting and Social Change

Volumn 77, Issue 2, 2010, Pages 203-217

  Amir Aslani, Arsia ^a   Mangematin, Vincent ^a  

^a GRENOBLE ECOLE DE MANAGEMENT   (France)

Author keywords

Biomarkers; Diagnostics; Innovation; Personalized medicine; Theranostics

Indexed keywords

CLINICAL RESEARCH; CRITICAL COMPONENT; CURRENT RATE; DELIVERY SYSTEMS; DISEASE PROGRESSION; DRUG DISCOVERY; DRUG TARGETS; HUMAN GENOME PROJECT; MEDICAL CONDITIONS; NEW TECHNOLOGIES; PERSONALIZED MEDICINE; PERSONALIZED MEDICINES; TERM VALUE; THERANOSTICS;

BIOMARKERS; HEALTH CARE;

DIAGNOSIS;

BIOMARKER; COMMERCIALIZATION; DISEASE TREATMENT; DRUG DEVELOPMENT; INNOVATION; MEDICINE; TECHNOLOGICAL DEVELOPMENT;

EID: 73749084284     PISSN: 00401625     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.techfore.2009.09.005     Document Type: Article

References (45)

1. Amir-Aslani A. Toxicogenomics predictive modelling: emerging opportunities for more efficient drug discovery and development. Technol. Forecast. Soc. Change 7 (2008) 905-932
2. Cho W.C.S. Proteomics technologies and challenges. Genomics, Proteomics & Bioinformatics 5 (2007) 77-85
3. Heath J.R., Davis M.E., and Hood L. Nanomedicine targets cancer. Sci. Am. (February 2009) 44-51
4. Shillingford C.A., and Vose C.W. Effective decision-making: progressing compounds through clinical development. Drug Discov. Today 6 (2001) 941-946
5. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today 6 (2001) 357-366
6. Nassar A.E.F., Kamel A.M., and Clairmont C. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov. Today 9 (2004) 1055-1064
7. Oberemm A., Onyon L., and Gundert-Remy U. How can toxicogenomics inform risk assessment. Toxicol. Appl. Pharmacol. 207 (2005) S592-S598
8. Nevins J.R., and Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat. Rev. Genet. 8 (2007) 601-609
9. Marchetti S., and Schellens J.H.M. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer 97 (2007) 577-581
10. Czerepak E.A., and Ryser S. Drug approvals and failures: implications for alliances. Nat. Rev. Drug Discov. 7 (2008) 197-198
11. McLean L.A., Gathmann I., Capdeville R., Polymeropoulos M.H., and Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with Imatinib. Clin. Cancer Res. 10 (2004) 155-165
12. Claudio J.O., and Stewart A.K. Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma. Am. J. Pharmacogenomics 5 (2005) 35-43
13. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
14. Dickson M., and Gagnon J.P. Key factors in the rising cost of drug discovery and development. Nat. Rev. Drug Discov. 3 (2004) 417-429
15. Bains W. Failure rates in drug discovery and development: will we ever get any better?. Drug Discov. World (Fall 2004) 9-18
16. Herman G.A., Stein P.P., Thornberry N.A., and Wagner J.A. Dipeptidyl peptidase- 4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther. 81 (2007) 761-767
17. Kaitin K.I. Fastest drug developers consistently best peers on key performance metrics. Tufts Center Study Drug Development Impact report vol. 8 (2006)
18. Wagner J.A. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 631-651
19. Lazarou J., Pomernaz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279 (1998) 1200-1205
20. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., and Bor D.H. Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287 (2002) 2215-2220
21. Stevens J.L., and Baker T.K. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov. Today 14 (2009) 162-167
22. Ryan T.P., Stevens J.L., and Thomas C.E. Strategic applications of toxicogenomics in early drug discovery. Curr. Opin. Pharmacol. 8 (2008) 654-660
23. Cohen M.H., et al. United States Food and Drug Administration Drug Approval Summary: Gefitnib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10 (2004) 1212-1218
24. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., et al. (2R)-4-oxo-4-[3 (trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2 amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48 (2005) 141-151
25. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., et al. Effect of single oral doses of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, or incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91 (2006) 4612-4619
26. Scott R., Wu M., Sanchez M., and Stein P.P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract. 61 (2007) 1-10
27. Fogarty M. The reality of targeted therapies. The Scientist 16 (2002) 35
28. FDA, Innovation &Stagnation Challenge & Opportunity on the critical path to new medical products. March 2004. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
29. Baba Y. Development of novel biomedicine based on genome science. Eur. J. Pharm. Sci. 13 (2001) 3-4
30. Kubinyi H. Drug research: myths, hype and reality. Nat. Rev. Drug Discov. 2 (2003) 665-668
31. Noble D. Will genomics revolutionize pharmaceutical R&D?. Trends Biotechnol. 21 (2003) 333-337
32. Huang S.M., Kim M.-J., Goodsaid F., Frueh F., and Lesko L.J. Application of pharmacogenetics and pharmacogenomics in drug development and regulatory review genomics: fundamentals and applications. In: Choudhuri S., and Carlson D.B. (Eds). Informa (2008)
33. Cressey T.R., and Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect. Genet. Evol. 7 (2007) 333-342
34. Bepler G. Pharmacogenomics: a reality or still a promise?. Lung Cancer 54 (2006) S3-S7
35. Longley D.B., Allen W.L., and Johnston P.G. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta 1766 (2006) 184-196
36. Manolio T.A., and Collins F.S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu. Rev. Med. 60 (2009) 443-456
37. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116 (2007) 2563-2570
38. Carlquist J.F., and Anderson J.L. Warfarin pharmacogentics: up close and personalized. Therapy 5 (2008) 125-128
39. Horrobin D.F. Realism in drug discovery-could Cassandra be right?. Nat. Biotechnol. 19 (2001) 1099-1100
40. Hopkins M.M., Ibarreta D., Gaisser S., Enzing C.M., Ryan J., Martin P.A., Lewis G., Symone Detmar S.M., van den Akker-van Marle E., Hedgecoe A.M., Nightingale P., Dreiling M., Hartig K.J., Vullings W., and Forde T. Putting pharmacogenetics into practice. Nat. Biotechnol. 24 (2006) 403-410
41. Marsuina K. Biomarkers transform R&D. Genetic Engineering and Biotechnology News (2007) 2007
42. Melander O., Newton-Cheh C., Almgren P., Hedblad B., Berglund G., Engström G., Persson M., Smith G., Magnusson M., Christensson A., Struck J., Morgenthaler N.G., Bergmann A., Pencina M.J., and Wang T.J. Novel and conventional biomarkers for predicition of incident cardiovascular events in the community. J. Am. Med. Assoc. 302 (2009) 49-57
43. Amir-Aslani A. The quest for competitive sustainability: from technology sourcing to knowledge management. J. Technol. Manag. Innov. 4 (2009) 54-68
44. Twombly R. Identity crisis: finding, defining and integrating biomarkers. J. Natl. Cancer Inst. 98 (2006) 11-12
45. Shafer S.M., Jeff Smith H., and Linder J.C. The power of business models. Bus. Horiz. 48 (2005) 199-207